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ABSTRACT: Under development are new techniques that have
the potential to define subpopulations of patients which may or
may not respond to targeted therapy. Better definition of resis-
tance mechanisms against monoclonal antibodies or tyrosine
kinase inhibitors will be one approach to achieve this goal. Pro-
gress has been made in the detection of these mechanisms when
targeting the epidermal growth factor (EGF) receptor family. Pro-
teomics either performed by imaging techniques or by methods
such as matrix-assisted desorption/ionisation time-of-flight
(MALDI-TOF) mass spectrometry requires further standardisation
and validation. A mass spectroscopy-based pre-treatment patient
selection system is under development that is highly reproducible
and capable of classifying patients by survival.
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Only a fraction of patients respond initially to therapy (primary
resistance), and those who do, often lose their response to tar-
geted therapy with time (secondary resistance). The postulated
mechanisms behind targeted therapy and development of resis-
tance were explored and the epidermal growth factor receptor
(EGFR) family was used as an example. The ErbB or epidermal
growth factor (EGF) family of receptor tyrosine kinases consists
of four members: EGFR (Erb1/HER-1), HER-2 (ErbB1/neu), HER-3
(ErbB3), and HER-4 (ErbB4). ErbB receptor tyrosine kinases are
attractive targets for therapy. They initiate multiple signalling
pathways, and they are conveniently accessible on the cell sur-
face where they can be targeted with monoclonal antibodies.1
They have an ATP-binding site and are amenable to enzymatic
blockade. Mutations - often single amino acid replacements and
short deletions – in ErbB receptor genes can occur, as is the case
with non-small-cell lung cancer (NSCLC). Likewise, overexpres-
sion of ErbB proteins occurs in a fraction of carcinomas, including
ErbB-2 overexpression in about a third of breast cancers. Cetux-
imab (Erbitux), panitumumab (Vectibix) and trastuzumab (Her-
ceptin) are all examples of anti-ErbB monoclonal antibodies in
clinical use. The potential mechanisms of trastuzumab action
include
– recruitment of natural killer (NK) cells to Her-2 overexpressing
tumour cells;
– reduction of Her-2 signalling to the phosphatidylinositol-3
kinase (PI3K), Src, or mTOR pathways;
– inhibition of angiogenesis and vasculature normalisation,
thereby improving delivery of chemotherapeutic drugs such
as paclitaxel (Taxol);
– enhancing receptor endocytosis and degradation;
– other hypothesised mechanisms.
Perhaps the main mechanism of action is antibody-depen-
dent cellular cytotoxicity (ADCC) of tumour cells. Antibodies
attach to the tumour cell, then NK cells move in and destroy it.
Clynes compared knockout and wild-type mice and showed that
preferential activation of inhibitory Fc receptors enhanced
tumour responses to trastuzumab treatment.2 Mice without Fc
receptors were unable to recruit NK cells, hence the antibody dis-
played only partial inhibition of tumour growth.
Spiridon and colleagues used mice with severe combined
immune deficiency (SCID) to demonstrate synergistic anti-
tumour effect of a combination of monoclonal antibodies against
Her-2 that do not bind to the same epitope.3 The speaker pre-
sented studies performed in his laboratory, in collaboration with
M. Sela, showing that single monoclonal antibodies lead to some
down-regulation and degradation of EGFR, but certain combina-
tions completely destroy the receptor. A single monoclonal anti-
body leads only to dimer formation, yielding inefficient
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